K Ahmadi, PhD MBA: Following a post-doc position at the Ludwig Institute for Cancer Research (UCL) she managed a drug discovery collaboration with Astellas Pharma, focused on cancer therapies. She was part of team that founded Piramed Ltd, where her achievements included a major alliance with Genentech and acquisition by Roche for 10x return for investors. She has been on management team of several biotech companies internationally.

Dr. Cockerill has a Ph.D. in Organic Chemistry. After a Postdoc at Cornell University he joined the Wellcome Foundation and over the next 15 years contributed to and led drug discovery projects in Pesticides, Immunology, Virology and Oncology. His achievements include inventorship of Tykerb, marketed by GSK for breast cancer. Subsequently he joined Arrow Therapeutics where he and his team developed novel RSV therapeutics over a period of10 yrs

Professor Powell, a successful entrepreneur in biotech: during his time at Wolfson Institute for Biomedical Research (UCL), He set up Inpharmatica (now part of Galapagos NV), Ark Therapeutics (now LSE listed) and Arrow Therapeutics. Ken led AT from its foundation in 1988 to a successful trade sale to Astra Zeneca in 2006 for $150M. With over 30 years‟ experience in the pharma/biotech business, Ken is a well respected figure in UK biotech industry